Abstracts tagged "Raynaud’s phenomenon"

Abstract Number: 3004 • 2014 ACR/ARHP Annual Meeting
Autoantibody-Mediated Raynaud’s Phenomenon: Animal Model and Human Disease
Dana P. Ascherman^1,2, Yunjuan Zang³, Laisel Martinez⁴, Judith Pignac-Kobinger⁵, Irina Fernandez³ and Eric L. Greidinger^3,4, ¹Medicine/Rheumatology, University of Miami, Miami, FL, ²Rheumatology, Miami VAMC, Miami, FL, ³Rheumatology, University of Miami, Miami, FL, ⁴Miami VAMC, Miami, FL, ⁵University of Miami, Miami, FL
Background/Purpose: Raynaud’s Phenomenon (RP) is frequently seen in autoimmune conditions, but an autoimmune basis for RP has not been established. Methods: Sera derived from anti-RNP+…
Abstract Number: 1930 • 2014 ACR/ARHP Annual Meeting
The Value of Repeated Nailfold Capillaroscopy in Raynaud’s Phenomenon in Daily Practice: A Follow-up Study in the Netherlands
B. de Boer¹, J. Meijs¹, J. van Aken², T.W.J. Huizinga¹, A.a. Schouffoer³ and J.K. de Vries-Bouwstra⁴, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Rheumatology, Spaarne Ziekenhuis, Hoofddorp, Netherlands, ³Rheumatology, Haga Hospital, The Hague, Netherlands, ⁴Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose Nailfold capillaroscopy is an important tool to differentiate primary Raynaud's phenomenon (PRP) from secondary Raynaud's phenomenon (SRP). Based on possible transition from PRP to…
Abstract Number: 1927 • 2014 ACR/ARHP Annual Meeting
A Retrospective Look at the Recurrence of Digital Ulcers in Patients with Scleroderma after Discontinuation of Oral Treprostinil
Ami A. Shah¹, Elena Schiopu², Soumya Chatterjee³, Mary Ellen Csuka⁴, Tracy Frech⁵, Avram Goldberg⁶, Robert F. Spiera⁷, Stanford L. Peng⁸ and Virginia D. Steen⁹, ¹Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Rheumatology, University of Michigan, Ann Arbor, MI, ³Rheumatic and Immunologic Ds, Cleveland Clinic, Cleveland, OH, ⁴Rheumatology, Medical College of Wisconsin, Milwaukee, WI, ⁵Div of Rheumatology, University of Utah, Salt Lake City, UT, ⁶Div of Rheumatology, North Shore-LIJ Health System, Great Neck, NY, ⁷Rheumatology, Hospital for Special Surgery, New York, NY, ⁸Benaroya Research Institute/Virginia Mason, Seattle, WA, ⁹Department of Rheumatology, Georgetown University Medical Center, Washington, DC
Background/Purpose Ischemic digital ulcers (DU) occur in over 40% of systemic sclerosis (SSc) patients. Treprostinil diolamine, a newer prostacyclin analog that has been developed for…
Abstract Number: 1683 • 2014 ACR/ARHP Annual Meeting
Botulinum Toxin-a for the Treatment of Severe Raynaud Phenomenon
Lucía Ruiz Gutiérrez¹, Ana Pérez Gómez¹, Nuria Valdeolivas Casillas², Henry Moruno Cruz¹, Eduardo Cuende Quintana¹, Ana Sánchez Atrio¹, Ana Turrión Nieves¹, Atusa Movasat¹, Cristina Bohórquez Heras¹, Fernando Albarrán Hernández¹, Maria Liz Romero Bogado¹, Susana Medina Montalvo² and Melchor Álvarez de Mon¹, ¹Hospital Príncipe de Asturias, Immune System Diseases/Rheumatology department, Alcalá de Henares, Madrid, Spain, ²Hospital Príncipe de Asturias, Dermatology department, Alcalá de Henares, Madrid, Spain
Background/Purpose Raynaud's phenomenon (RP) is characterized by transient episodes of vasoconstriction of the arteries and arterioles of the extremities in response to cold or emotional…
Abstract Number: 1699 • 2014 ACR/ARHP Annual Meeting
Endothelial and Platelet Microparticles As Potential Novel Biomarkers of Peripheral Microvascular Dysfunction in Systemic Sclerosis and Primary Raynaud’s Phenomenon
John D. Pauling^1,2, Daniel Moreno-Martinez³, Fiona Wilkinson⁴, Ben Parker^5,6, Jacqueline A. Shipley¹, Darren Hart¹, Neil J McHugh^1,2 and Yvonne Alexander³, ¹Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ²Department of Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom, ³Healthcare Science Research Institute, Manchester Metropolitan University, Manchester, United Kingdom, ⁴School of Healthcare Science, Manchester Metropolitan University, Manchester, United Kingdom, ⁵Institute of Inflammation and Repair School of Translation Medicine The University of Manchester, Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester Academic Health Sciences Centre, Manchester, United Kingdom, ⁶Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester, United Kingdom
Background/Purpose Microparticles (MPs) are membrane-bound vesicles derived from vascular and intravascular cells such as endothelial cells (EMPs) and platelets (PMPs). MPs form during cell activation…
Abstract Number: 1701 • 2014 ACR/ARHP Annual Meeting
Short-Term Effects of Iloprost on Micro-Vessels Hemodynamics in Systemic Sclerosis Patients Evaluated By Laser Doppler Flowmetry
Florenzo Iannone, Cinzia Rotondo, Mariangela Nivuori, Emanuela Praino, Laura Coladonato, Michele Covelli and Giovanni Lapadula, DIM, Rheumatology Unit, Bari, Italy
Background/Purpose Iloprost is a milestone in the treatment of Raynaud’s Phenomenon (RP). However, it has transient hemodynamic effects due to a very short half-time, thereby…
Abstract Number: 1702 • 2014 ACR/ARHP Annual Meeting
Antiphospholipid Antibodies in Systemic Sclerosis: Prevalence and Clinical Significance?
Anjali Shetty¹, Suncica Volkov¹, Claudia Vergara² and William Swedler³, ¹Medicine/Rheumatology, University of Illinois at Chicago, Chicago, IL, ²Rheumatology, University of Illinois Chicago, Chicago, IL, ³Section of Rheumatology, University of Illinois at Chicago, Chicago, IL
Background/Purpose: Systemic Sclerosis (SSc) is an autoimmune disease characterized by collagen deposition and vascular changes of the skin and internal organs, leading ultimately to fibrosis. …
Abstract Number: 1680 • 2014 ACR/ARHP Annual Meeting
an Indirect Comparisons Analysis of Medications Used for Treatment of Raynaud’s Phenomenon
Sampath Manickam¹, Elie Donath², Sandeep Dayanand³ and Jonathan Greer⁴, ¹University of Miami Palm Beach Internal Medicine, West Palm Beach, FL, ²Internal Medicine, University of Miami Miller School of Medicine Palm Beach Regional Campus, Atlantis, FL, ³University of Miami Palm Beach Internal medicine, West palm beach, FL, ⁴Arthritis & Rheumatology Associates, Boynton Beach, FL
An Indirect Comparisons Analysis of Medications used for treatment of Raynaud’s phenomenonBackground/Purpose: There are several pharmacological treatments used for treatment of Raynaud’s phenomenon: calcium channel…
Abstract Number: 2597 • 2013 ACR/ARHP Annual Meeting
Acupressure For The Treatment Of Raynaud’s Phenomenon: A Pilot Randomized Controlled Trial
Heather Gladue¹, Richard E. Harris², Veronica Berrocal³, Pei-Suen Tsou⁴, Gautam Edhayan⁵, Ray Ohara⁵ and Dinesh Khanna⁶, ¹University of Michigan, Ann Arbor, MI, ²Anesthesiology, University of Michigan, Ann Arbor, MI, ³Department of Biostatistics- School of Public Health, University of Michigan, Ann Arbor, MI, ⁴Internal Medicine, Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, ⁵University of Michigan Medical School, Ann Arbor, MI, ⁶Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI
Background/Purpose: Raynaud’s phenomenon (RP) affects approximately 10% of the US population. The high cost, lack of efficacy, and side effects of conventional medical therapies necessitates…
Abstract Number: 2598 • 2013 ACR/ARHP Annual Meeting
Timing and Outcome Of Transition From Primary To Secondary Raynaud’s Phenomenon: A Capillaroscopic Based Study
Alberto Sulli¹, Giorgia Ferrari², Elena Bernero², Carmen Pizzorni², Vanessa Smith³, Barbara Ruaro² and Maurizio Cutolo⁴, ¹Research Laboratory and Academic Unit of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genoa, Italy, ²Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genoa, Italy, ³Department of Rheumatology, Ghent University Hospital, Ghent, Belgium, ⁴Internal medicine, Research Laboratory and Academic Unit of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genoa, Italy
Background/Purpose: Raynaud's phenomenon (RP) is classified as primary (PRP) or secondary (SRP) depending on its association with an underlying disease (1,2). PRP can evolve to…
Abstract Number: 2179 • 2013 ACR/ARHP Annual Meeting
Consensus: What Agent To Use When First-Line Vasodilatadors Fail In Raynaud´s Phenomenon Or Digital Ulcers Secondary To Juvenile Systemic Sclerosis?
Marìa M. Katsicas¹, Mariana Gonzalez² and Ricardo A. G. Russo³, ¹Immunology & Rheumatology., Hospital de Pediatrìa Garrahan, Buenos Aires, Argentina, ²Immunology & Rheumatology, Hospital de Pediatría Garrahan, Buenos Aires, Argentina, ³Immunology & Rheumatology, Hospital de Pediatria Garrahan, Buenos Aires, Argentina
Background/Purpose: Juvenile Systemic Sclerosis (JSS) is characterized by Raynaud`s phenomenon (RP) and digital ulcers (DU).Conventional therapy includes calcium channel blockers (CCB). A growing number of…
Abstract Number: 1813 • 2013 ACR/ARHP Annual Meeting
Evaluation Of The Effect Of Sildenafil On The Microvascular Blood Flow and On The Endothelial Progenitor Cells In Patients With Early Systemic Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Study
Fernando V. Andrigueti, Pâmela C.C. Ebbing, Maria I. Arismendi and Cristiane Kayser, Rheumatology Division, Universidade Federal de São Paulo, São Paulo, Brazil
Background/Purpose: Phosphodiesterase-5 inhibitors have been successfully used for the treatment of Raynaud’s phenomenon (RP) in patients with systemic sclerosis (SSc). However, no study has evaluated…
Abstract Number: 853 • 2013 ACR/ARHP Annual Meeting
Capillaroscopy Compared With Color Doppler Ultrasound Of Digital Arteries For Distinguishing Primary From Secondary Raynaud’s Phenomenon
Wolfgang A. Schmidt¹, Katharina Pagel², Bernd Schicke³ and Andreas Krause⁴, ¹Med Ctr Rheumatology Berlin Buch, Immanuel Krankenhaus Berlin, Berlin, Germany, ²Medical Ctr Rheumatol Berlin Buch, Immanuel Krankenhaus Berlin, Berlin, Germany, ³Tumorzentrum Berlin, Berlin, Germany, ⁴Immanuel Krankenhaus Berlin, Berlin, Germany
Background/Purpose: Raynaud’s phenomenon (RP) is commonly seen in rheumatology practice. Differentiating primary from secondary RP is important for disease management and prognosis. How does capillaroscopy…
Abstract Number: 703 • 2013 ACR/ARHP Annual Meeting
Correlation Between Patient Self-Report Of Symptoms Of Raynaud’s Phenomenon and Objective Assessment Of Digital Microvascular Perfusion Using Infrared Thermography
Marina Scolnik^1,2, Bhavisha Vasta², Darren Hart², Jacqueline A. Shipley², Sue Brown², Eleanor Korendowych², Neil J McHugh^2,3 and John D. Pauling^2,3, ¹Rheumatology Section, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ²Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ³Department of Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom
Background/Purpose: Patient self-report of digital colour changes form the basis of a clinical diagnosis of Raynaud's phenomenon (RP) and help classify patients with early systemic…
Abstract Number: 704 • 2013 ACR/ARHP Annual Meeting
Evaluating The Effects Of Combination Aspirin and Dipyridamole (asasantin retard) On Platelet Function, Oxidative Stress and Peripheral Vascular Function In Primary Raynaud’s Phenomenon and Systemic Sclerosis
John D. Pauling¹, Jacqueline A. Shipley¹, Darren Hart¹, Ginger L. Milne² and Neil J McHugh^1,3, ¹Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ²Division of Clinical Pharmacology, Vanderbilt University School of Medicine, Nashville, TN, ³Department of Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom
Background/Purpose: There is evidence of enhanced platelet activation in Raynaud’s phenomenon (RP), particularly in systemic sclerosis (SSc). Upon activation, platelets release vasoconstrictive mediators (e.g. thromboxane…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].